1.Vyas AK, Sharma BC, Sarin SK, et al. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients. Liver Int. 2018;38(1):38-49.
2.Zhou P, Xu J, Dai M, et al. The immunosuppressive effects of CD4(+) CD25(+) regulatory T cells on dendritic cells in patients with chronic hepatitis B. J Viral Hepat. 2018;25(6):733-41.
3.Pan CQ ZJ. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):36-40.
4.Ganem D PA. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118-29.
5.Peeridogaheh H, Meshkat Z, Habibzadeh S, et al. Current concepts on immunopathogenesis of hepatitis B virus infection. Virus Res. 2018;245:29-43.
6.Liu Y, Gao LF, Liang XH, et al. Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol. 2016;22(7):2294-303.
7.Sun HH, Zhou DF, Zhou JY. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J Med Virol. 2016;88(1):13-20.
8.Golsaz-Shirazi F, Amiri MM, Shokri F. Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection. Rev Med Virol. 2018;28(6):e2007.
9.Liu N, Liu B, Zhang L, et al. Recovery of circulating CD56(dim) NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg. Int Immunopharmacol. 2018;62:59-66.
10.Li Q, Lu F, Deng G, et al. Modeling the effects of covalently closed circular DNA and dendritic cells in chronic HBV infection. J Theor Biol. 2014;357:1-9.
11.Pietrzak-Nguyen A, Piradashvili K, Fichter M, et al. MPLA-coated hepatitis B virus surface antigen (HBsAg) nanocapsules induce vigorous T cell responses in cord blood derived human T cells. Nanomedicine. 2016;12(8):2383-94.
12.van der Molen RG, Sprengers D, Binda RS, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 2004;40(3):738-46.
13.Fonteneau JF, Larsson M, Beignon AS, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol. 2004;78(10):5223-32.
14.Woltman AM, Op den Brouw ML, Biesta PJ, et al. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One. 2011;6(1):e15324.
15.Zheng BJ ZJ, Qu D, Siu KL, Lam TW, Lo HY, Lee SS, Wen YM. Selective functional deficit in dendritic cell – T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat. 2004;11(3):217-24.
16.Hurk EAaSvDL-vd. Future considerations for dendritic cell immunotherapy against chronic viral infections. Clin Immunol 2014.
17.Faure-Dupuy S, Lucifora J, Durantel D. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. Viruses. 2017;9(5).
18.Cao W. Molecular characterization of human plasmacytoid dendritic cells. J Clin Immunol. 2009;29(3):257-64.
19.Tang F, Du Q, Liu YJ. Plasmacytoid dendritic cells in antiviral immunity and autoimmunity. Sci China Life Sci. 2010;53(2):172-82.
20.Cao WH, Li MH, Pan CQ, et al. Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. J Interferon Cytokine Res. 2018;38(5):197-205.
21.Li MH, Zhang L, Zhang D, et al. Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection. Chin Med J (Engl). 2018;131(1):43-49.
22.Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005;202(2):203-7.
23.Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100(7):1111-9.
24.Agrawal S, Gollapudi P, Elahimehr R, et al. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant. 2010;25(3):737-46.
25.Obregon C, Rothen-Rutishauser B, Gerber P, et al. Active uptake of dendritic cell-derived exovesicles by epithelial cells induces the release of inflammatory mediators through a TNF-alpha-mediated pathway. Am J Pathol. 2009;175(2):696-705.
26.Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204(1):11-20.
27.Pei RJ, Chen XW, Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol. 2014;20(33):11618-29.
28.Cui G, Chen J, He J, et al. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens. Drug Des Devel Ther. 2015;9:3003-16.
29.Hu W, Jain A, Gao Y, et al. Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation. Proc Natl Acad Sci U S A. 2015;112(45):13994-9.
30.Xie Q, Shen HC, Jia NN, et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect. 2009;11(4):515-23.
31.Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19(1):24-32.
32.Iwakiri D, Zhou L, Samanta M, et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med. 2009;206(10):2091-9.
33.Klaschik S, Gursel I, Klinman DM. CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Mol Immunol. 2007;44(6):1095-104.
34.Hoebe K, Beutler B. TRAF3: a new component of the TLR-signaling apparatus. Trends in Molecular Medicine. 2006;12(5):187-89.
35.Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med. 2006;203(8):1999-2008.
36.Ma Z, Liu J, Wu W, et al. The IL-1R/TLR signaling pathway is essential for efficient CD8(+) T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol Immunol. 2017;14(12):997-1008.